POLITICS: On Thursday, President Joe Biden delivers information to the US puublic in regard to matters associated with prescription drug affordability and the apparent effects of price gouging by drug producers. Today, President Biden commented in regard to the impact of support by Americans that is adfforded the drug manufacturers who fail, thereafter at maintaining affordability to those who purchase prescription and other OTC medicines. By Michelle Crawford-Sapenter "I believe if tax payers fund the development of new medicines, they ought to be able to afford it." --US President Joe Biden
Today, Biden stated his administration is taking action to ensure that Americans can afford the medicines they pay taxes to have developed. Biden stated that the administration is taking on drug companies that gouge consumers.
According to research conduicted by the Biden -Harris administration, it was found that invariably, tax payers supported drug makers and supported the federally funded resarch that would provide the essential information for drug companies to produce medicines.
The administration discovered that big pharma companies will charge any prioce --often too high--for the prescription drugs that are the biproduct of the federally funded research.
Having studied the information gathered from data that has transpired over years and years of federally funded research and prescription drug production, the Biden-Harris administration drug companies routinely make medicines inaccessable due to too high prices.
The results of the Biden-Harris administration's research arrives at the administration's considering whether the answer to preventing prescrkiption drug price gouging by means of creating a license for competing companies to sell the same drug for less.
Biden stated, also, that today's action is "all about ..." the possibility of taking action involving the possibility of licensing competing companies.
During a White House briefing held today, President Biden encouraged RSV drug makers to work diligently to move forward with the rapid production of the RSV innoculation for infants. Biden's encpouragement aimed at AsteaZeneca, Sanofi and Thermo Fischer reflect the administration's plans for the development of 77,000 additional doses of the RSV imminization drug.
Comentarios